MESO Mesoblast Limited gains 21% Oct 2, 2018

Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on specialized cells, known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory conditions, orthopedic disorders, and oncologic/hematologic conditions. The company's lead product candidates include MPC-150-IM, a Phase 3 product candidate under investigation for the treatment of chronic congestive heart failure; MPC-06-ID, a Phase 3 product candidate under investigation for the treatment of chronic low back pain due to disc degeneration; MSC-100-IV, a Phase 3 intravenously-delivered product candidate, which is developed for the treatment of acute graft versus host disease following allogeneic bone marrow transplantation; and MPC-300-IV, an intravenously-delivered immunomodulatory product candidate for the treatment of chronic inflammatory conditions, including biologic-refractory rheumatoid arthritis, and diabetic nephropathy, which is under Phase 2 trial. It has a collaboration agreement with JCR Pharmaceuticals Co., Ltd to offer TEMCELL HS. Inj., a product based on its proprietary mesenchymal lineage adult stem cell technology for the treatment of graft versus host disease. The company has operations in Australia, the United States, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited was founded in 2004 and is based in Melbourne, Australia.http://www.priceseries.com/trade/MESO-Mesoblast-Limited-stock-gains-21-percent-a-Trade-Record-by-priceSeries-2018091720181002.html